Case | Age/sex | Diagnosis | Splenomegaly | BCR-ABL1* | Karyotype |
---|---|---|---|---|---|
1 | 59/F | CML-T | No | Pos | 46,XX,t(9;22)(q34;q11.2)[16]/46,XX[4] |
2 | 57/F | CML-T | No | Pos | 46,XX,t(9;22)(q34;q11.2)[16]/46,XX[4] |
3 | 88/M | CML-T | No | Pos | 46,XY,t(9;22)(q34;q11.2)[20] |
4 | 72/F | CML-T | No | Pos | 46,XX,t(9;22)(q34;q11.2)[18]/46,XX[2] |
5 | 64/M | CML-T | Yes, 3–4 cm | Pos | 46,XY,t(9;22)(q34;q11.2)[20] |
6 | 26/F | CML-T | No | Pos | No growth |
7 | 59/F | CML-T† | Yes, by CT | Pos‡ | 45–46,XX,t(9;22)(q34;q11.2),-10,inc[cp3]‡ |
Pos§ | 46,XX,add(17)(p12)[17]/46,XX[15]§ | ||||
8 | 47/F | CML | Yes, to pelvis | Pos | NA |
9 | 57/M | CML | Yes, 2 cm | Pos | 46,XY,t(9;22)(q34;q11.2)[9]/45,idem,-Y[11] |
10 | 52/M | CML | No | Pos | 46,XY,t(9;22)(q34;q11.2)[12]/45,idem,-Y[8] |
11 | 40/F | CML | No | Pos | 46,XX,t(9;22)(q34;q11.2)[20] |
12 | 30/M | CML-BC | No | Pos | 46,XY,t(9;22)(q34;q11.2),inv(17) (p13q23)[19]/47,idem,del(7)(q11.2),+21[2] |
*By interphase fluorescence in situ hybridisation.
†Thrombocytosis developed while on tyrosine kinase inhibitor therapy.
‡At diagnosis.
§27 months after initial diagnosis.
CML, chronic myelogenous leukaemia in chronic phase; CML-BC, chronic myelogenous leukaemia in blast crisis; CML-T, chronic myelogenous leukaemia with thrombocytosis; F, female; M, male; NA, not available; Pos, positive.